Telemedicine diagnosis of acute respiratory tract infection patients is not inferior to face-to-face consultation: a randomized trialRandomized Controlled Trial Published on 2022-05-272022-10-05 Journal: Einstein [Category] 임상, [키워드] 1:1 Accuracy acute respiratory symptom age Analysis Care chronic heart classification COVID-19 COVID-19 pandemic diagnose Diagnosis diagnostic distribution enrolled evaluated exclusion group Health Immunosuppressed Infection initial Lung diseases molecular no difference Patient patients primary endpoint Randomized randomized trial respiratory infection respiratory symptom respiratory tract infection RT-PCR Secondary endpoints statistically study group subsequent Telemedicine telemedicine consultation upper respiratory tract women [DOI] 10.31744/einstein_journal/2022AO6800 PMC 바로가기 [Article Type] Randomized Controlled Trial
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses코로나19 입원 환자를 위한 렘데시비르 및 기타 3가지 약물: WHO 연대 무작위 시험의 최종 결과 및 업데이트된 메타 분석Meta-Analysis Published on 2022-05-212022-09-11 Journal: Lancet (London, England) [Category] 신약개발, 임상, 치료제, [키워드] 1:1 allocation Analysis antiviral drugs assigned average both groups Characteristics Compliance controls country COVID-19 COVID-19 diagnosis database death died discharge discharged disease severity drug drugs eligible patient Endpoint enrolled exclusion Final futility hospital Hospital mortality hospitalised hospitalised patient Hospitalised patients Hydroxychloroquine in both groups in-hospital mortality Inpatient Inpatients interferon ISRCTN Kaplan-Meier Local Lopinavir meta-analyses Meta-analysis Mortality mortality analysis mortality rate ratio no significant effect occurred Open-label outcome oxygen participant Patient patients patients with COVID-19 Placebo placebos primary endpoint progressed progression proportion randomisation Randomised trial Randomly rate ratio receive recruited regions Registered Remdesivir reported secondary Secondary endpoints solidarity Solidarity trial Standard of care study drug the WHO treatment period Trial Ventilated Ventilation were given WHO [DOI] 10.1016/S0140-6736(22)00519-0 PMC 바로가기 [Article Type] Meta-Analysis
Study protocol for a single-centre randomised controlled trial to investigate the effect of lung recruitment in paediatric patients after cardiac surgery심장 수술 후 소아 환자에서 폐 모집의 효과를 조사하기 위한 단일 센터 무작위 대조 시험에 대한 연구 프로토콜Article Published on 2022-05-172022-09-11 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome after cardiac surgery approval arrhythmia arterial oxygen tension article barotrauma cardiac Cardiac surgery China clinical trial Compliance conferences Critical Critical care decrease determine Ethics ethics committee fraction guidelines Hospital stay Hypotension hypoxaemic respiratory failure IMPROVE Intensive intensive care intensive care unit lung recruitment mechanical ventilation Mortality non-invasive ventilation Occurrence oxygen Oxygenation Paediatric cardiac surgery Paediatric intensive & paediatric patient paediatric patients PaO Patient peer-reviewed postoperative primary endpoint protocol protocols protocols & pulmonary complications randomised controlled trial Randomly reduce registration number respiratory distress Respiratory failure Respiratory system secondary endpoint Secondary endpoints Serious Adverse Event Serious Adverse Events syndrome Trial university Ventilator-free days West [DOI] 10.1136/bmjopen-2022-063278 PMC 바로가기 [Article Type] Article
Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patientsCOVID-19 입원 환자에서 코펩틴 및 중부 프로아드레노메둘린의 예후 가치Article Published on 2022-05-012022-09-11 Journal: European Journal of Clinical Investigation [Category] MERS, 바이오마커, [키워드] Acute kidney injury Admission AUROC Biomarkers Care complications copeptin coronavirus disease Coronavirus disease 2019 COVID-19 database death Diagnosis eligible endothelial function expressed hazard ratio help Hospital mortality identify In-hospital in-hospital complication in-hospital complications in-hospital mortality intensive care intensive care unit interquartile range marker median mid-regional proadrenomedullin Mortality MR-proADM non-survivor Non-survivors outcome outcomes Patient patients hospitalized Pneumonia predict predicted predictive power primary endpoint Prognosis Receiver operator characteristic risk stratification secondary endpoint Secondary endpoints Sepsis Septic shock Stress survivor was increased were assessed with COVID-19 [DOI] 10.1111/eci.13753 PMC 바로가기 [Article Type] Article
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases전신 염증성 질환이 있는 면역 저하 환자에서 알파 및 델타 변이체에 대한 BNT162b2 백신의 면역원성Article Published on 2022-05-012022-09-11 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] abrogated Alpha alpha and delta variants analysed anti-spike antibodies anti-spike antibody anti-Spike IgG B-cell B.1.617.2 BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections Control controls COVID-19 Delta delta variant Delta variants dose effort Endpoint evaluate exhibiting healthcare humoral Humoral response Immune escape immunocompromised individual immunocompromised individuals Immunocompromised patient Immunocompromised patients immunogenicity impairing IMPROVE individual infected with SARS-CoV-2 Inflammatory diseases Kinetics methotrexate mounted neutralisation neutralising Neutralising activity of BNT162b2 Other Patient primary endpoints Prospective raise regimen responses rituximab SARS-CoV-2 secondary Secondary endpoints sera Seroconversion Specific T-cell response strain Strains Support systemic inflammatory disease systemic inflammatory diseases T-cell T-cell Response T-cell responses therapeutic treated vaccination Vaccine Viral viral fitness [DOI] 10.1136/annrheumdis-2021-221508 PMC 바로가기 [Article Type] Article
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients경증 및 중등도 입원 코비드-19 환자를 위한 인도메타신의 공개 라벨 무작위 임상 시험Randomized Controlled Trial Published on 2022-04-192022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료법, 치료제, [키워드] addition adjuvant therapies Admission adverse event afebrile anti-inflammatory drug Antiviral Arm ARMS Block randomisation blood chemistry clinical trial control arm coronavirus disease cough COVID-19 COVID-19 patient Desaturation discharge effective Efficacy and safety evaluated Fever Follow-up High-flow oxygen hospital hospitalised indomethacin Ivermectin medication Mild moderate myalgia open label Paracetamol parameters Patient patients primary endpoint profile provided randomised randomized clinical trial reported required retained Safe Secondary endpoints Standard of care Symptom symptomatic tiredness [DOI] 10.1038/s41598-022-10370-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial간경변 환자에서 양성자 펌프 억제제 치료 중단(STOPPIT): 전향적, 다기관, 대조, 무작위, 이중 맹검 시험을 위한 연구 프로토콜Article Published on 2022-04-122022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 bleeding bleeding event cirrhosis clinical Clinical outcome clinical outcomes clinical trial complications composite endpoint control group death defined Diagnosis double-blind trial double-blinded Effect Endpoint Esomeprazole EU Clinical Trials EudraCT evaluate excluded gastritis gastrointestinal bleeding Germany Hemorrhagic hepatic Hepatic encephalopathy Hospitalization Hospitalized Hypothesis IMPROVE include increased risk indication infections Infectious complications inhibitor intervention group intestinal liberal liver Liver cirrhosis liver failure manifestation medication microbiota Mortality multicentre observational studies observational study Occurrence outcome Pantoprazole parallel-group Patient peptic ulcer Placebo placebo-controlled PPI primary composite endpoint Prophylactic Proton-pump inhibitors Randomized rationale receive recruitment reflux esophagitis Registered risk secondary Secondary endpoints Side-effects STOP Study protocol therapy Treatment Trial variable Withdrawal [DOI] 10.1186/s13063-022-06232-w PMC 바로가기 [Article Type] Article
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19Clinical Trial Published on 2022-04-082022-10-05 Journal: Med (New York, N.Y.) [Category] 바이오마커, 임상, [키워드] accelerated acute respiratory distress acute respiratory distress syndrome addition alpha-1 antitrypsin Anti-inflammatory ARDS biochemically changes in circulating Clinical outcome clinical trial Concentration coronavirus COVID-19 Cytokines develop double-blind EudraCT feasible febrile Grifols groups IL-10 IL-1β IL-6 IL-8 Inflammation interleukin-6 intravenous moderate Mortality multicenter Necrosis patients patients receiving placebo patients with COVID-19 phase 3 trial Placebo placebo-controlled trial plasma primary endpoint pro-inflammatory progression Randomized randomized control trial randomized control trial. receive receptor reduce Safe Secondary endpoints severe ARDS severe coronavirus disease Support syndrome the placebo group therapeutic Tolerability Treatment treatment group Trial ventilator ventilator-free day was increased were assessed [DOI] 10.1016/j.medj.2022.03.001 PMC 바로가기 [Article Type] Clinical Trial
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452IgG-Fc 융합 COVID-19 서브유닛 백신 AKS-452에 대한 I/II상 연구의 I상 중간 결과Clinical Trial Published on 2022-02-232022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 AKS-452 Alpha alpha and delta variants anti-SARS-CoV-2 Antigen caused Cell Cohort cohorts cold chain complex conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta variants distribution dose Endpoint Fc-fusion fusion protein healthy human IgG1 Fc IgG titer IgG titers immunogenicity assessments Infection Infectious disease Live virus mutant neutralization potency occurred Open-label pandemic phase Phase I primary endpoints profile Prophylaxis reactogenicity receiving Receptor binding domain respiratory SAE SAEs SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 viral infection secondary endpoint Secondary endpoints seroconversion rates severe acute respiratory syndrome Coronavirus single-center Single-dose skewed Spike protein subject subunit Subunit vaccine Support the SARS-CoV-2 vaccination Vaccine Viral viral infections viral spike protein virus infection [DOI] 10.1016/j.vaccine.2022.01.043 PMC 바로가기 [Article Type] Clinical Trial
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer Research Published on 2022-02-112022-10-05 Journal: British Journal of Cancer [Category] 바이오마커, [키워드] 95%CI bevacizumab Biomarker Cancer clinical Combination effective expression monotherapy ovarian cancer participant Patient predict Predictive primary endpoint randomised receive regimen Result RP2 Secondary endpoints significantly stratified subgroup analysis Trial Trial registration TUBB3 [DOI] 10.1038/s41416-022-01717-6 [Article Type] Research